Savior LLC’s Cytokinetics CYTK Stock Holding History

Savior LLC’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3	Closed	-$106	–	138
2023 Q1	$106	Buy	+3	New	+$122	﹤0.01%	161

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Savior LLC's CYTK Position: Q2 2023 in Review

Savior LLC sold out of Cytokinetics (CYTK) in Q2 2023, closing a stake of 3 shares — an estimated $106 sold.

Savior LLC first reported a position in CYTK in Q1 2023 and held it in 1 quarter. The position peaked at $106 in Q1 2023. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

Savior LLC reported no remaining Cytokinetics position as of Q2 2023 after selling out during the quarter.
Savior LLC sold 3 Cytokinetics shares in Q2 2023, an estimated $106.
Savior LLC first reported a position in Cytokinetics in Q1 2023 and held it in 1 quarter.
Savior LLC's Cytokinetics position peaked at $106 in Q1 2023.
253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on Savior LLC's 13F filing for Q2 2023, filed 7 Jul 2023.